Izvorni znanstveni članak

https://doi.org/10.3325/cmj.2019.60.109

Glia in amyotrophic lateral sclerosis and spinal cord injury: common therapeutic targets

Jelena Ban orcid.org/0000-0001-5792-3998 ; Laboratory for Molecular Neurobiology, Department of Biotechnology, University of Rijeka, Rijeka, Croatia
Cynthia Sámano orcid.org/0000-0002-8909-9582 ; Laboratorio de Biología Celular, Departamento de Ciencias Naturales, Universidad Autónoma Metropolitana, Unidad Cuajimalpa, Mexico City, Mexico
Miranda Mladinić orcid.org/0000-0002-3985-6629 ; Laboratory for Molecular Neurobiology, Department of Biotechnology, University of Rijeka, Rijeka, Croatia
Ivana Munitić orcid.org/0000-0002-5171-9950 ; Laboratory for Molecular Immunology, Department of Biotechnology, University of Rijeka, Croatia

Sažetak

The toolkit for repairing damaged neurons in amyotrophic
lateral sclerosis (ALS) and spinal cord injury (SCI) is extremely
limited. Here, we reviewed the in vitro and in vivo studies
and clinical trials on nonneuronal cells in the neurodegenerative
processes common to both these conditions. Special
focus was directed to microglia and astrocytes, because
their activation and proliferation, also known as neuroinflammation,
is a key driver of neurodegeneration. Neuroinflammation
is a multifaceted process that evolves during
the disease course, and can be either beneficial or toxic
to neurons. Given the fundamental regulatory functions of
glia, pathogenic mechanisms in neuroinflammation represent
promising therapeutic targets. We also discussed neuroprotective,
immunosuppressive, and stem-cell based approaches
applicable to both ALS and SCI.

Ključne riječi

Hrčak ID:

239736

URI

https://hrcak.srce.hr/239736

Datum izdavanja:

15.4.2019.

Posjeta: 1.145 *